Fidelity, Arch support, RNAi emerging player City Therapeutics (CTY.US) aims for US IPO, plans to raise up to 185 millions dollars

智通财经2026/10/09 12:36

Show original

According to Jinse Finance, early-stage RNAi drug developer City Therapeutics Inc. (CTY.US) is seeking to raise up to 184.7 millions USD in its U.S. initial public offering (IPO). According to documents filed with the U.S. Securities and Exchange Commission on Friday, the company, whose investors include Arch Venture Partners and Fidelity Management & Research, plans to issue 9.72 million shares at a price range of $17 to $19 per share.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.